March 13, 2024

In a phase I trial, interleukin-1 receptor-associated kinase 4 degrader was found to have robust clinical activity and a favorable safety profile in hidradenitis suppurativa and atopic dermatitis patients. Inflammation driven by toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs) is involved in the pathophysiology of hidradenitis suppurativa (HS) and atopic dermatitis (AD). IL-1R-associated kinase 4...